Holen Sie sich die Stockscreener-App
100.49
1.11%
-1.13
Handel nachbörslich:
100.49
Schlusskurs vom Vortag:
$101.62
Offen:
$98.98
24-Stunden-Volumen:
1.88M
Relative Volume:
0.58
Marktkapitalisierung:
$19.43B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-27.46
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
-4.14%
1M Leistung:
+4.71%
6M Leistung:
+152.68%
1J Leistung:
+162.10%
1-Tages-Spanne:
$97.61
$102.36
1-Wochen-Bereich:
$95.25
$107.45
52-Wochen-Spanne:
$29.17
$124.49
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
650-481-6801
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
100.49 | 19.65B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines, Inc. $RVMD Shares Purchased by Legato Capital Management LLC - MarketBeat
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Rating of "Buy" from Brokerages - MarketBeat
RVMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Revolution Medicines Doubles Down on Costly RAS Push - TipRanks
Broker proposes sale of 3,000 RVMD shares (NASDAQ: RVMD) — Form 144 - Stock Titan
Mark A. Goldsmith sells 15,394 shares (RVMD) via Form 144 - Stock Titan
Insider Form 144: 30,000-share option transaction for RVMD (RVMD) - Stock Titan
Revolution Medicines, Inc. (RVMD) Stock Analysis: Navigating the Highs of a 27% Potential Upside - DirectorsTalk Interviews
Revolution Medicines, Inc. $RVMD Shares Bought by Rafferty Asset Management LLC - MarketBeat
Revolution Medicines, Inc. (RVMD) Net Loss Widens amid Progress on Clinical Trial Programs - Insider Monkey
Can Revolution Medicines Inc outperform in the next rallyWeekly Volume Report & Weekly Top Performers Watchlists - baoquankhu1.vn
Revolution Medicines, Inc. $RVMD Shares Bought by TD Asset Management Inc - MarketBeat
UBS Adjusts Revolution Medicines Price Target to $145 From $71, Maintains Buy Rating - marketscreener.com
Is RVMD’s Big Losses and Massive Equity Plans Reshaping the Investment Case for Revolution Medicines (RVMD)? - Yahoo Finance
Truist Adjusts Price Target on Revolution Medicines to $116 From $99, Maintains Buy Rating - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Coverage Initiated at UBS Group - MarketBeat
Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating - marketscreener.com
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform Rating – Here’s Why - Insider Monkey
Evercore ISI Initiates Revolution Medicines (RVMD) With an Outperform RatingHere's Why - Bitget
RVMD Sees Target Price Uplift from Piper Sandler Analyst | RVMD Stock News - GuruFocus
Piper Sandler Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock - MarketBeat
Wells Fargo & Company Raises Revolution Medicines (NASDAQ:RVMD) Price Target to $144.00 - MarketBeat
RVMD: Wells Fargo Raises Price Target to $144 with Overweight Ra - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Shares Gap Down on Disappointing Earnings - MarketBeat
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View - Finviz
Piper Sandler raises Revolution stock price target on drug confidence By Investing.com - Investing.com Nigeria
Revolution Medicines (NASDAQ:RVMD) Given New $145.00 Price Target at Needham & Company LLC - MarketBeat
Westfield Capital Management Co. LP Buys 864,563 Shares of Revolution Medicines, Inc. $RVMD - MarketBeat
Analyst Maintains "Buy" Rating but Lowers Price Target for RVMD - GuruFocus
Revolution Medicines, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Has Revolution Medicines (RVMD) Found a Breakthrough in Cancer Treatment? - Yahoo Finance
Mizuho Trims Price Target on Revolution Medicines to $140 From $143, Keeps Outperform Rating - marketscreener.com
Revolution Medicines (NASDAQ:RVMD) Upgraded by Evercore to Strong-Buy Rating - MarketBeat
Revolution Medicines Q4 Earnings Call Highlights - MarketBeat
Revolution Medicines Inc (RVMD) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus
Revolution Medicines Inc files for common stock offering of up to $1.0 billion - marketscreener.com
Revolution Medicines Q4 2025 Earnings Call Transcript - MarketBeat
Revolution Medicines (RVMD) Advances Pipeline with Strong Financ - GuruFocus
Revolution Medicines (NASDAQ:RVMD) Announces Quarterly Earnings Results - MarketBeat
Revolution Medicines (RVMD) Earnings Transcript - AOL.com
Revolution Medicines Inc Files For Common Stock Offering Of Up To $1.0 Billion - TradingView
Earnings call transcript: Revolution Medicines Q4 2025 reveals strategic growth - Investing.com
Revolution Medicines (RVMD) Advances Clinical Progress in Cancer Treatments - GuruFocus
Revolution Medicines (RVMD) Projects Significant Operating Expen - GuruFocus
Revolution Medicines Q4 Loss Widens - marketscreener.com
Earnings Flash (RVMD) Revolution Medicines Posts Q4 Loss $1.86, vs. FactSet Est of $1.58 Loss - marketscreener.com
Revolution Medicines Q4 net loss widens - TradingView
Revolution Medicines (RVMD) details RAS-targeted cancer drug pipeline - Stock Titan
BRIEF-Revolution Medicines Q4 EPS USD -1.86 - TradingView
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress - ChartMill
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.71%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):